InnovoSIL Inc. reported that its InnovoSIL™-1 silver periodate antimicrobial compound acts as an excellent antimicrobial against Candida auris. C. auris is an emerging fungus (yeast) causing a serious global health threat due to its resistance to antibiotic treatments and its tendency to cause severe illness in people with weakened immune systems. C. auris infections have been associated with 30-60% mortality rates in hospitalized patients. Coated onto a wound dressing model, InnovoSIL®?-1 silver prevented a broad spectrum of microorganisms from adhering to the dressing surface over time under clinically relevant conditions, while eliminating surrounding planktonic (free-floating) microorganisms. Other organisms tested included superbugs well-known for causing difficult-to-treat infections that tend to spread rapidly in healthcare settings: Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus facadeecalis (VRE), Coagulase Negative Staphylococcus epidermidis (CONS), and Acinetobacter baumannii.

The evaluation was performed using Innovotech's proprietary BEST Assay™? testing system, which is included in its scope of accreditation under ISO 17025:2017.